Astaxanthin composition for treating xerophthalmia as well as preparation method and application of astaxanthin composition

Abstract

The invention belongs to the field of xerophthalmia treatment, and relates to an astaxanthin composition for treating xerophthalmia as well as a preparation method and application thereof, and the astaxanthin composition comprises the following components in parts by weight: 25-35 parts of astaxanthin, 20-30 parts of algal polysaccharides, 5-10 parts of salidroside, 2-3 parts of menthol, 1-2 parts of borneol and 0.5-1 part of xanthophyll. The composition comprises the astaxanthin, the algal polysaccharides, the salidroside, the menthol, the borneol and the xanthophyll, and the components act together, especially the astaxanthin, the algal polysaccharides and the salidroside act synergistically, so that the composition has a remarkable curative effect in the aspect of treating the xerophthalmia, and the symptoms of the xerophthalmia can be effectively relieved. In addition, compared with some artificially synthesized medicines, the composition disclosed by the invention is prepared from natural biomass, so that the composition is relatively safe in use and low in side effect.

Description

Technical Field

[0001] The present invention relates to the technical field of dry eye treatment, and in particular to an astaxanthin composition for treating dry eye, a preparation method and application thereof. Background Art

[0002] Dry eye is a common eye disease characterized by insufficient tear secretion, rapid evaporation, or abnormal tear composition. Symptoms of dry eye include eye pain, foreign body sensation, blurred vision, dryness, etc. In severe cases, patients may experience symptoms such as eye burning, soreness, redness, eye pain, and photophobia. Therefore, timely and effective treatment of dry eye is needed.

[0003] With the changes in lifestyle in modern society, factors such as long-term use of electronic screens and air-conditioned environments have aggravated the incidence of dry eye. At present, the treatments for dry eye mainly include the following:

[0004] 1. Artificial tear eye drops: This is the most commonly used method to relieve symptoms, which reduces eye dryness and discomfort by replenishing tears.

[0005] 2. Oral medications: Certain oral medications can increase tear secretion or improve tear quality.

[0006] Although the above treatment methods can relieve the symptoms of dry eye to a certain extent, they also have some limitations and side effects. For example, long-term use of artificial tears may cause a certain burden on the cornea, and oral medications may cause adverse reactions.

[0007] Astaxanthin is widely present in the biological world and is one of the main carotenoids in marine organisms. Astaxanthin is one of the strongest known antioxidants, and its antioxidant capacity far exceeds that of other antioxidants such as vitamin E and β-carotene. It can remove free radicals, protect cells from oxidative damage, improve the body's immunity, and slow down skin aging. Astaxanthin is mostly used in the eyes to relieve visual fatigue and prevent myopia. Existing technologies rarely use astaxanthin to treat dry eyes.

[0008] Therefore, it is necessary to develop a product containing astaxanthin that can effectively treat dry eye syndrome and reduce side effects. Summary of the invention

[0009] 1. Technical issues to be resolved

[0010] In order to solve the problems in the prior art of poor therapeutic effect and side effects of artificial tears and oral medications for treating dry eyes, the present invention provides an astaxanthin composition for treating dry eyes, a preparation method and application thereof.

[0011] (II) Technical solution

[0012] In order to achieve the above object, the main technical solutions adopted by the present invention include:

[0013] In a first aspect, the present invention provides an astaxanthin composition for treating dry eye, comprising, by weight, 25-35 parts of astaxanthin, 20-30 parts of seaweed polysaccharides, 5-10 parts of salidroside, 2-3 parts of menthol, 1-2 parts of borneol and 0.5-1 part of lutein; the astaxanthin is encapsulated by nanoliposomes.

[0014] The astaxanthin composition for treating dry eye as described above preferably comprises, by weight, 30 parts of astaxanthin, 25 parts of seaweed polysaccharides, 8 parts of salidroside, 3 parts of menthol, 2 parts of borneol and 1 part of lutein.

[0015] The astaxanthin composition for treating dry eye as described above preferably further comprises 1-2 portions of vitamin C.

[0016] In a second aspect, the present invention provides a method for preparing the above-mentioned astaxanthin composition, comprising the following steps:

[0017] S1: Provides astaxanthin encapsulated by nanoliposomes;

[0018] S2: mixing seaweed polysaccharide, salidroside, menthol, borneol and lutein to obtain a mixture;

[0019] S3: mixing the astaxanthin encapsulated by the nanoliposomes with the mixture to obtain a composition.

[0020] In the method for preparing the astaxanthin composition as described above, preferably, in step S1, astaxanthin, lecithin and cholesterol are dissolved in an organic solvent, mixed evenly and then the organic solvent is removed to obtain a uniform lipid film; then an aqueous solution is added to the lipid film to hydrate the lipid film, followed by ultrasonic treatment to obtain astaxanthin encapsulated by nanoliposomes.

[0021] In the method for preparing the astaxanthin composition as described above, preferably, in step S1, the mass ratio of astaxanthin, lecithin and cholesterol is (200-300):(10-20):(50-100);

[0022] The organic solvent is ethanol; the mixed system of astaxanthin, lecithin, cholesterol and the organic solvent is subjected to rotary evaporation under a reduced pressure of 40-60 mbar and a temperature of 40-42° C. to remove the organic solvent.

[0023] In the method for preparing the astaxanthin composition as described above, preferably, in step S1, the aqueous phase solution is a phosphate buffer solution, and the volume mass ratio v:w of the aqueous phase solution to the lipid film is (2-3) mL:1 g;

[0024] The power of ultrasonic treatment is 150-200 W, the time of ultrasonic treatment is 6-10 min, and there is a pause of 20-30 s after each treatment of 1-2 min.

[0025] In a third aspect, the present invention provides a use of the above-mentioned astaxanthin composition or the astaxanthin composition prepared by the above-mentioned preparation method in an eye patch.

[0026] In a fourth aspect, the present invention provides a use of the above-mentioned astaxanthin composition or the astaxanthin composition prepared by the preparation method according to any one of claims 4 to 7 in eye drops or eye ointments.

[0027] In a fifth aspect, the present invention provides a use of the above-mentioned astaxanthin composition or the astaxanthin composition prepared by the preparation method described in any one of claims 4 to 7 in a nasal mucosal ointment.

[0028] (III) Beneficial effects

[0029] The composition of the present invention includes astaxanthin, seaweed polysaccharide, salidroside, menthol, borneol and lutein, which work together to effectively treat dry eye and relieve the symptoms of dry eye. In addition, compared with some synthetic drugs, the composition of the present invention is derived from natural biomass, which is safer to use and has low side effects.

[0030] The astaxanthin in the present invention has a synergistic effect with seaweed polysaccharides and salidroside. Compared with a single or two effective components, the combined effect of astaxanthin, seaweed polysaccharides and salidroside ensures that the composition of the present invention has a better therapeutic effect on dry eye. DETAILED DESCRIPTION

[0031] In order to better explain the present invention and facilitate understanding, the present invention is described in detail below in conjunction with specific implementation methods.

[0032] The invention provides an astaxanthin composition for treating dry eyes, which comprises, by weight, 25-35 parts of astaxanthin, 20-30 parts of seaweed polysaccharide, 5-10 parts of salidroside, 2-3 parts of menthol, 1-2 parts of borneol and 0.5-1 part of lutein.

[0033] Preferably, in parts by weight, the astaxanthin composition for treating dry eye includes 30 parts of astaxanthin, 25 parts of seaweed polysaccharides, 8 parts of salidroside, 3 parts of menthol, 2 parts of borneol and 1 part of lutein, and 1-2 parts of vitamin C may be added.

[0034] The functions of the components in the astaxanthin composition of the present invention are as follows:

[0035] Astaxanthin: As a powerful antioxidant, it can scavenge free radicals, protect eye cells from damage by free radicals, reduce ocular inflammation, maintain the integrity of the barrier, and accelerate the repair of eye tissues.

[0036] Seaweed polysaccharide: It has natural antioxidant properties, can provide good moisturizing effect, help maintain a moist environment in the eyes, form a protective film in the eyes, reduce water evaporation, thereby increasing the stability of the tear film, and can also help build and strengthen the eye barrier and promote the repair of eye tissue.

[0037] Salidroside: It has anti-fatigue and immunomodulatory effects, helps reduce eye inflammation, improves the health of eye tissue by enhancing local blood circulation and nutrient supply, and strengthens the defense mechanism of the eye barrier through immunomodulatory effects.

[0038] Menthol and borneol: can bring a cooling sensation, relieve eye discomfort, and also have a certain anti-inflammatory effect.

[0039] Lutein: It can protect retinal cells, prevent macular degeneration, and also has antioxidant and anti-inflammatory effects.

[0040] The various components of the astaxanthin composition of the present invention work together to have a significant therapeutic effect in treating dry eye and can effectively relieve the symptoms of dry eye. Compared with some synthetic drugs, the components of the composition of the present invention are derived from natural biomass, which is safer to use and has fewer side effects.

[0041] The astaxanthin in the present invention has a synergistic effect with seaweed polysaccharides and salidroside. Compared with a single one or two effective components, the combined effect of astaxanthin, seaweed polysaccharides and salidroside ensures that the composition of the present invention has a better therapeutic effect on dry eye. The lack of any one or two of the components will reduce the therapeutic effect of dry eye.

[0042] Although astaxanthin is a powerful antioxidant, it is sensitive to light, heat and oxygen and is easily degraded. Therefore, it is further preferred that the astaxanthin in the above-mentioned astaxanthin composition can be encapsulated by nanoliposomes.

[0043] Nanoliposomes can provide a stable microenvironment for astaxanthin, protect astaxanthin from external factors, and extend its shelf life and use period. In addition, nanoliposomes can also achieve sustained release of astaxanthin, so that astaxanthin is gradually released in the eye and continues to work, reducing the need for frequent medication. During use, nanoliposomes can increase the permeability and retention time of astaxanthin in eye tissues, thereby improving its bioavailability.

[0044] The preparation method of the above-mentioned astaxanthin composition comprises the following steps:

[0045] S1: Provides astaxanthin encapsulated by nanoliposomes.

[0046] S2: Mix seaweed polysaccharide, salidroside, menthol, borneol and lutein to obtain a mixture. In this step, seaweed polysaccharide, salidroside, menthol, borneol and lutein can be dissolved in a small amount of deionized water or buffer solution to be mixed with astaxanthin encapsulated by nanoliposomes.

[0047] S3: mixing the astaxanthin encapsulated by the nanoliposomes with the mixture to obtain a composition.

[0048] Preferably, the above step S1 specifically comprises: dissolving astaxanthin, lecithin and cholesterol in an organic solvent, mixing them evenly and removing the organic solvent to obtain a uniform lipid film, then adding an aqueous solution to the lipid film to hydrate the lipid film, and then performing ultrasonic treatment to obtain astaxanthin encapsulated by nanoliposomes.

[0049] The mass ratio of astaxanthin, lecithin and cholesterol is (200-300):(10-20):(50-100), and the organic solvent is ethanol. Specifically, the mixed system of astaxanthin, lecithin, cholesterol and the organic solvent is subjected to rotary evaporation under a reduced pressure of 40-60 mbar and a temperature of 40-42° C. to remove the organic solvent.

[0050] The aqueous solution is preferably a phosphate buffer solution, the volume mass ratio v:w of the aqueous solution to the lipid film is (2-3) mL:1 g, and the lipid film is prepared into nanoliposomes by ultrasonic dispersion, the power of the ultrasonic treatment is 150-200 W, the time of the ultrasonic treatment is 6-10 min, and the treatment is paused for 20-30 s after each 1-2 min treatment. The lipid film includes the total weight of lecithin, astaxanthin and cholesterol.

[0051] As the main component of lipid membrane, lecithin has good biocompatibility. Cholesterol can be inserted into the bilayer structure of lecithin and regulate the fluidity and stability of the membrane by interacting with phospholipid molecules. Cholesterol can make the liposome membrane more stable and less prone to rupture, which helps to improve the encapsulation rate of astaxanthin and also improve the biocompatibility of nanoliposomes.

[0052] The aqueous solution used in the present invention is preferably a phosphate buffer solution, and the pH value of the phosphate buffer solution is generally about 7.4, which is very important for maintaining the stability of the liposomes and can prevent lipid aggregation or degradation. The addition of the phosphate buffer solution can hydrate the lipid membrane, help the liposomes to be evenly dispersed in the aqueous phase, and ensure that the formed liposomes have a good particle size distribution.

[0053] The astaxanthin composition provided by the present invention or the astaxanthin composition prepared by the above preparation method can be applied to eye patches, eye drops and eye ointments. Specifically, the raw materials required for the preparation of the corresponding products can be added to the liquid composition to obtain eye patches, eye drops and eye ointments. In the process of preparing eye patches, eye drops and eye ointments, potassium sorbate can also be added as a preservative, and sodium hyaluronate with good water retention capacity can be added. In addition, the astaxanthin composition provided by the present invention or the astaxanthin composition prepared by the above preparation method can be applied to nasal mucosa ointment, which can be applied to the nasal mucosa for use.

[0054] In order to further clarify the scheme of the present invention and its technical advancement, the following is a description in conjunction with specific embodiments and technical effects.

[0055] Example 1

[0056] This embodiment provides an astaxanthin composition for treating dry eye, which comprises, by weight, 30 parts of astaxanthin, 25 parts of seaweed polysaccharides, 8 parts of salidroside, 3 parts of menthol, 2 parts of borneol and 1 part of lutein.

[0057] The preparation method of the astaxanthin composition of this embodiment is as follows:

[0058] S1: Dissolve astaxanthin, lecithin and cholesterol in ethanol, mix well, and then perform rotary evaporation on the mixed system in a rotary evaporator at 50 mbar and 40° C. to remove ethanol and obtain a uniform lipid film. The mass ratio of astaxanthin, lecithin and cholesterol is 250:25:75.

[0059] Then, phosphate buffer was added to the lipid film, followed by ultrasonic treatment, the power of the ultrasonic treatment was 150 W, the time of ultrasonic treatment was 8 min, and a pause of 20 s was made after each treatment of 1 min, to obtain astaxanthin encapsulated by nanoliposomes. The volume mass ratio v:w of phosphate buffer to lipid film was 2.5 mL:1 g.

[0060] S2: Dissolve seaweed polysaccharide, salidroside, menthol, borneol and lutein in phosphate buffer to obtain a mixture.

[0061] S3: mixing the astaxanthin encapsulated by the nanoliposomes with the mixture to obtain a composition.

[0062] Example 2

[0063] This embodiment provides an astaxanthin composition for treating dry eye, which includes, by weight, 25 parts of astaxanthin, 20 parts of seaweed polysaccharides, 5 parts of salidroside, 2 parts of menthol, 1 part of borneol and 0.5 part of lutein.

[0064] The preparation method of the astaxanthin composition of this embodiment is as follows:

[0065] S1: Dissolve astaxanthin, lecithin and cholesterol in ethanol, mix well, and then perform rotary evaporation on the mixed system in a rotary evaporator at 60 mbar and 42° C. to remove ethanol and obtain a uniform lipid film. The mass ratio of astaxanthin, lecithin and cholesterol is 200:10:50.

[0066] Then, phosphate buffer was added to the lipid film, followed by ultrasonic treatment, the power of ultrasonic treatment was 200 W, the time of ultrasonic treatment was 6 minutes, and a pause of 30 seconds was made after each treatment of 2 minutes, to obtain astaxanthin encapsulated by nanoliposomes. The volume mass ratio v:w of phosphate buffer and lipid film was 3mL:1g.

[0067] S2: Dissolve seaweed polysaccharide, salidroside, menthol, borneol and lutein in phosphate buffer to obtain a mixture.

[0068] S3: mixing the astaxanthin encapsulated by the nanoliposomes with the mixture to obtain a composition.

[0069] Example 3

[0070] This embodiment provides an astaxanthin composition for treating dry eye, which includes, by weight, 35 parts of astaxanthin, 30 parts of seaweed polysaccharides, 10 parts of salidroside, 2.5 parts of menthol, 1.2 parts of borneol and 0.8 parts of lutein.

[0071] The preparation method of the astaxanthin composition of this embodiment is as follows:

[0072] S1: Dissolve astaxanthin, lecithin and cholesterol in ethanol, mix well, and then perform rotary evaporation on the mixed system in a rotary evaporator at 40 mbar and 41° C. to remove ethanol and obtain a uniform lipid film. The mass ratio of astaxanthin, lecithin and cholesterol is 300:20:100.

[0073] Then, phosphate buffer was added to the lipid film, followed by ultrasonic treatment, the power of ultrasonic treatment was 180W, the time of ultrasonic treatment was 10min, and a pause of 20s was made after each treatment of 1min, to obtain astaxanthin encapsulated by nanoliposomes. The volume mass ratio v:w of phosphate buffer and lipid film was 2mL:1g.

[0074] S2: Dissolve seaweed polysaccharide, salidroside, menthol, borneol and lutein in phosphate buffer to obtain a mixture.

[0075] S3: mixing the astaxanthin encapsulated by the nanoliposomes with the mixture to obtain a composition.

[0076] Example 4

[0077] This embodiment provides an astaxanthin composition for treating dry eye, which comprises, by weight, 28 parts of astaxanthin, 26 parts of seaweed polysaccharides, 6 parts of salidroside, 2 parts of menthol, 1 part of borneol and 0.6 parts of lutein.

[0078] The preparation method of the astaxanthin composition of this embodiment is as follows:

[0079] S1: Dissolve astaxanthin, lecithin and cholesterol in ethanol, mix well, and then perform rotary evaporation on the mixed system in a rotary evaporator at 45 mbar and 41° C. to remove ethanol and obtain a uniform lipid film. The mass ratio of astaxanthin, lecithin and cholesterol is 230:16:60.

[0080] Then, phosphate buffer was added to the lipid film, followed by ultrasonic treatment, the power of ultrasonic treatment was 160W, the time of ultrasonic treatment was 7 minutes, and a pause of 30 seconds was made after each treatment of 2 minutes, to obtain astaxanthin encapsulated by nanoliposomes. The volume mass ratio v:w of phosphate buffer and lipid film was 2.28mL:1g.

[0081] S2: Dissolve seaweed polysaccharide, salidroside, menthol, borneol and lutein in phosphate buffer to obtain a mixture.

[0082] S3: mixing the astaxanthin encapsulated by the nanoliposomes with the mixture to obtain a composition.

[0083] Comparative Example 1

[0084] This comparative example provides an astaxanthin composition for treating dry eye, which differs from Example 1 in that the astaxanthin content is 0.

[0085] Comparative Example 2

[0086] This comparative example provides an astaxanthin composition for treating dry eye, which is different from Example 1 in that the content of seaweed polysaccharide is 0.

[0087] Comparative Example 3

[0088] This comparative example provides an astaxanthin composition for treating dry eye, which is different from Example 1 in that the content of salidroside is 0.

[0089] Test 1:

[0090] 1. Animal preparation:

[0091] Several healthy BALB / c mice aged 8 weeks were selected (mice with corneal problems, abnormal fluorescence staining, and large differences in tear secretion between the two eyes were eliminated) and randomly divided into blank control group, negative control group, experimental group 1, experimental group 2, experimental group 3, experimental group 4, experimental group 5, experimental group 6, and experimental group 7. There were 6 mice in each group, and the number of eyes in each group was 12. The average value of the number of eyes was used to calculate the corneal staining score below.

[0092] 2. Dry eye modeling and medication:

[0093] The mice in the blank control group were raised normally without any treatment.

[0094] 0.2% benzalkonium chloride solution was dripped into the eyes of mice in the negative control group and experimental groups 1 to 7 three times a day for 14 consecutive days to induce dry eye.

[0095] Dosage:

[0096] Blank control group: normal feeding without any treatment.

[0097] Negative control group: normal saline was dripped every day.

[0098] Experimental Group 1 to Experimental Group 7: Each group was instilled with eye drops made from the compositions prepared in Examples 1-4 and Comparative Examples 1-3.

[0099] Dosage schedule: 3 times a day for 14 consecutive days.

[0100] 3. Result detection:

[0101] On the 15th day after the dry eye model was established, the blank control mice and the mice that completed the modeling were stained with a 0.25% sodium fluorescein solution. Specifically, the 0.25% sodium fluorescein solution was allowed to stay on the ocular surface of each group of mice for 10 seconds, and then the excess dye was rinsed with a 0.9% sodium chloride solution. The ocular surface was wiped dry with a cotton swab, and the slit lamp light source was adjusted to cobalt blue light. The eyeballs of each group of mice were exposed to the slit lamp for observation. After adjusting the magnification, photos were taken to record the coloring of the sodium fluorescein dye on the cornea of ​​small mice in different groups. The cornea of ​​the mouse was divided into 4 quadrants: superior temporal, inferior temporal, superior nasal, and inferior nasal. Each quadrant was scored according to 0-3 points. The score of each cornea was the sum of the scores of the 4 quadrants. The scoring results are shown in Table 1. The corneal staining scores in Table 1 are mean ± standard deviation. The scoring rules are as follows: no staining is 0 points; 1-30 punctate staining (mild) is 1 point; more than 30 punctate staining but the staining is not fused (moderate) is 2 points; corneal punctate staining fusion, filaments and ulcers (severe) is 3 points.

[0102] Table 1 Statistics of corneal staining scores in the blank group, negative control group and each experimental group

[0103]

[0104] The lower the corneal score, the higher the degree of corneal epithelial repair of the mouse and the better the eye recovery. The higher the score, the more severe the corneal damage.

[0105] As can be seen from Table 1, the cornea of ​​mice in the blank control group that did not undergo modeling and drug administration always remained at a normal level. The corneal epithelial staining area of ​​mice in the negative control group and experimental groups 1 to 7 increased significantly after modeling. Without additional drug administration, the corneal epithelial staining area of ​​mice in the negative control group increased further after 14 days. After 14 days of drug administration, the corneal epithelial staining area of ​​mice in experimental groups 1 to 4 returned to normal levels. The degree of repair of the corneal epithelial staining area of ​​mice in experimental groups 5-7 was not obvious, indicating that astaxanthin, seaweed polysaccharides and salidroside have a synergistic effect, and the therapeutic effect is better than that of a single one or two effective components.

[0106] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. An astaxanthin composition for treating dry eyes, characterized in that: According to weight, it comprises 25-35 parts of astaxanthin, 20-30 parts of seaweed polysaccharide, 5-10 parts of salidroside, 2-3 parts of menthol, 1-2 parts of borneol and 0.5-1 part of lutein; the astaxanthin is encapsulated by nanoliposomes.

2. The astaxanthin composition for treating dry eye according to claim 1, characterized in that: Calculated by weight, it includes 30 parts of astaxanthin, 25 parts of seaweed polysaccharides, 8 parts of salidroside, 3 parts of menthol, 2 parts of borneol and 1 part of lutein.

3. The astaxanthin composition for treating dry eye according to claim 1, characterized in that: Also includes 1-2 servings of Vitamin C.

4. A method for preparing the astaxanthin composition according to any one of claims 1 to 3, characterized in that: The steps include: S1: Provides astaxanthin encapsulated by nanoliposomes; S2: mixing seaweed polysaccharide, salidroside, menthol, borneol and lutein to obtain a mixture; S3: mixing the astaxanthin encapsulated by the nanoliposomes with the mixture to obtain a composition.

5. The method for preparing the astaxanthin composition according to claim 4, characterized in that: In step S1, astaxanthin, lecithin and cholesterol are dissolved in an organic solvent, mixed evenly and then the organic solvent is removed to obtain a uniform lipid film; then an aqueous solution is added to the lipid film to hydrate the lipid film, followed by ultrasonic treatment to obtain astaxanthin encapsulated by nanoliposomes.

6. The method for preparing the astaxanthin composition according to claim 5, characterized in that: In step S1, the mass ratio of astaxanthin, lecithin and cholesterol is (200-300):(10-20):(50-100); The organic solvent is ethanol; the mixed system of astaxanthin, lecithin, cholesterol and the organic solvent is subjected to rotary evaporation under a reduced pressure of 40-60 mbar and a temperature of 40-42° C. to remove the organic solvent.

7. The method for preparing the astaxanthin composition according to claim 5, characterized in that: In step S1, the aqueous phase solution is a phosphate buffer solution, and the volume mass ratio v:w of the aqueous phase solution to the lipid membrane is (2-3) mL:1 g; The power of ultrasonic treatment is 150-200 W, the time of ultrasonic treatment is 6-10 min, and there is a pause of 20-30 s after each treatment of 1-2 min.

8. Use of the astaxanthin composition according to any one of claims 1 to 3 or the astaxanthin composition prepared by the preparation method according to any one of claims 4 to 7 in an eye patch.

9. Use of the astaxanthin composition according to any one of claims 1 to 3 or the astaxanthin composition prepared by the preparation method according to any one of claims 4 to 7 in eye drops or eye ointments.

10. Use of the astaxanthin composition according to any one of claims 1 to 3 or the astaxanthin composition prepared by the preparation method according to any one of claims 4 to 7 in nasal mucosal ointment.

Images